Follow-up study of second-line treatments for Parkinson's disease
Part of Brain & nervous system clinical trials.
This study follows people with Parkinson's disease who are starting a second-line treatment — like deep brain stimulation, an apomorphine pump, or a duodopa pump — to see how these treatments work over time and how they affect daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Parkinson's disease (not another type of Parkinsonism).
- You experience motor fluctuations (wearing-off) or involuntary movements (dyskinesia).
- Your doctor has said you need a second-line treatment like deep brain stimulation, an apomorphine pump, or a duodopa pump.
- You are older than 21 years.
- You have a score above 20 on a memory and thinking test (called MoCA).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new form of Parkinson's medication given through a pump to see how well it works in everyday life for people in the early stages of advanced Parkinson's. It may help control symptoms and improve daily function.
This study looks at a new pump treatment (foslevodopa/foscarbidopa) for people with advanced Parkinson's who are having motor fluctuations. It aims to see if it improves quality of life when started earlier in the advanced stage.
This study follows people with Parkinson's disease who still have movement symptoms despite taking medication. It aims to understand how the disease changes over time, which could help improve future treatments.
This trial tests a new treatment called DSP-1083 for people with Parkinson's disease whose symptoms are not well controlled with standard medications. The study will check if it is safe and if it helps improve movement and daily function.
This trial is for people with Parkinson's disease or multiple system atrophy (parkinsonian type) who took part in an earlier AB-1005 study. It will continue to monitor your health over time to learn more about the treatment's long-term effects.
This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.